These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

652 related items for PubMed ID: 29779881

  • 1. Failure of Tafamidis to Halt Progression of Ala36Pro TTR Oculomeningovascular Amyloidosis.
    Salvi F, Volpe R, Pastorelli F, Bianchi A, Vella A, Rapezzi C, Mascalchi M.
    J Stroke Cerebrovasc Dis; 2018 Sep; 27(9):e212-e214. PubMed ID: 29779881
    [Abstract] [Full Text] [Related]

  • 2. Monitoring effectiveness and safety of Tafamidis in transthyretin amyloidosis in Italy: a longitudinal multicenter study in a non-endemic area.
    Cortese A, Vita G, Luigetti M, Russo M, Bisogni G, Sabatelli M, Manganelli F, Santoro L, Cavallaro T, Fabrizi GM, Schenone A, Grandis M, Gemelli C, Mauro A, Pradotto LG, Gentile L, Stancanelli C, Lozza A, Perlini S, Piscosquito G, Calabrese D, Mazzeo A, Obici L, Pareyson D.
    J Neurol; 2016 May; 263(5):916-924. PubMed ID: 26984605
    [Abstract] [Full Text] [Related]

  • 3. Effects of tafamidis treatment on transthyretin (TTR) stabilization, efficacy, and safety in Japanese patients with familial amyloid polyneuropathy (TTR-FAP) with Val30Met and non-Val30Met: A phase III, open-label study.
    Ando Y, Sekijima Y, Obayashi K, Yamashita T, Ueda M, Misumi Y, Morita H, Machii K, Ohta M, Takata A, Ikeda S.
    J Neurol Sci; 2016 Mar 15; 362():266-71. PubMed ID: 26944161
    [Abstract] [Full Text] [Related]

  • 4. Tafamidis: a selective transthyretin stabilizer to treat wild-type ATTR amyloidosis and hereditary ATTR amyloidosis with cardiomyopathy.
    Paton DM.
    Drugs Today (Barc); 2019 Dec 15; 55(12):727-734. PubMed ID: 31942875
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Effects of tafamidis on transthyretin stabilization and clinical outcomes in patients with non-Val30Met transthyretin amyloidosis.
    Merlini G, Planté-Bordeneuve V, Judge DP, Schmidt H, Obici L, Perlini S, Packman J, Tripp T, Grogan DR.
    J Cardiovasc Transl Res; 2013 Dec 15; 6(6):1011-20. PubMed ID: 24101373
    [Abstract] [Full Text] [Related]

  • 7. Long-term treatment of transthyretin familial amyloid polyneuropathy with tafamidis: a clinical and neurophysiological study.
    Planté-Bordeneuve V, Gorram F, Salhi H, Nordine T, Ayache SS, Le Corvoisier P, Azoulay D, Feray C, Damy T, Lefaucheur JP.
    J Neurol; 2017 Feb 15; 264(2):268-276. PubMed ID: 27878441
    [Abstract] [Full Text] [Related]

  • 8. Tafamidis (Vyndaqel): a light for FAP patients.
    Nencetti S, Rossello A, Orlandini E.
    ChemMedChem; 2013 Oct 15; 8(10):1617-9. PubMed ID: 24000164
    [Abstract] [Full Text] [Related]

  • 9. Brain Microbleeds 12 Years after Orthotopic Liver Transplantation in Val30Met Amyloidosis.
    Salvi F, Pastorelli F, Plasmati R, Morelli C, Rapezzi C, Bianchi A, Mascalchi M.
    J Stroke Cerebrovasc Dis; 2015 Jun 15; 24(6):e149-51. PubMed ID: 25802113
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Transthyretin (ATTR) amyloidosis: clinical spectrum, molecular pathogenesis and disease-modifying treatments.
    Sekijima Y.
    J Neurol Neurosurg Psychiatry; 2015 Sep 15; 86(9):1036-43. PubMed ID: 25604431
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Long-term effects of tafamidis for the treatment of transthyretin familial amyloid polyneuropathy.
    Coelho T, Maia LF, da Silva AM, Cruz MW, Planté-Bordeneuve V, Suhr OB, Conceiçao I, Schmidt HH, Trigo P, Kelly JW, Labaudinière R, Chan J, Packman J, Grogan DR.
    J Neurol; 2013 Nov 15; 260(11):2802-14. PubMed ID: 23974642
    [Abstract] [Full Text] [Related]

  • 18. Transthyretin deposition in the eye in the era of effective therapy for hereditary ATTRV30M amyloidosis.
    Buxbaum JN, Brannagan T, Buades-Reinés J, Cisneros E, Conceicao I, Kyriakides T, Merlini G, Obici L, Plante-Bordeneuve V, Rousseau A, Sekijima Y, Imai A, Waddington Cruz M, Yamada M.
    Amyloid; 2019 Mar 15; 26(1):10-14. PubMed ID: 30675806
    [Abstract] [Full Text] [Related]

  • 19. Early intervention with tafamidis provides long-term (5.5-year) delay of neurologic progression in transthyretin hereditary amyloid polyneuropathy.
    Waddington Cruz M, Amass L, Keohane D, Schwartz J, Li H, Gundapaneni B.
    Amyloid; 2016 Sep 15; 23(3):178-183. PubMed ID: 27494299
    [Abstract] [Full Text] [Related]

  • 20. Tafamidis in the Treatment of ATTR-related Cardiomyopathy: Indications and Grey Zones.
    Capovilla TM, Lalario A, Rossi M, Porcari A, Aimo A, Limongelli G, Emdin M, Merlo M, Sinagra G.
    Heart Fail Clin; 2024 Jul 15; 20(3):333-341. PubMed ID: 38844304
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 33.